📰 Thomas Biegi News
Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
April 29, 2024
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 20...
April 24, 2024
EQS-News: MorphoSys AG / Key word: Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting...
April 24, 2024
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April...
April 11, 2024
EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal MorphoSys’ Management Board and Supervisory ...
March 13, 2024
EQS-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01...
February 6, 2024
Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize...
February 6, 2024
Germany - MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG based on Novartis intention to submit a voluntary public...
January 30, 2024
EQS-News: MorphoSys AG / Key word: Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...
January 30, 2024
EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability 30.01.2024 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Mu...
January 8, 2024
EQS-News: MorphoSys AG / Key word: Conference MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 08.01.2024 / 08:00 CET/CEST The issuer is...